On 6 March 2026, Japan approved the world’s first iPS stem cell treatments for Parkinson’s and severe heart failure. Could ...

Japan approves world-first iPS cell therapies for heart failure, Parkinsons Conditional approvals speed Japans first iPS treatments into clinics for heart failure and Parkinsons ...

Japan has formally approved the world’s first regenerative medical products utilizing induced pluripotent stem (iPS) cells, paving the way for use in patients as early as this summer.

Pharmaceutical company Sumitomo Pharma said it received the green light for the manufacture and sale of Amchepry, its ...

Japan has approved the world’s first stem cell therapy for Parkinson’s disease, offering new hope for millions globally. The treatment uses induced pluripotent stem (iPS) cells to replace damaged ...

Japan has approved ground-breaking stem-cell treatments for Parkinson's and severe heart failure, one of the manufacturers ...

Japan has granted approval to Sumitomo Pharma’s stem cell based Parkinson’s therapy Amchepry, the first iPS cell derived regenerative treatment for the disease, offering a new option for patients who ...

The Japanese government on Friday conditionally approved the commercialization of two regenerative medicine products prepared ...

Japan's health ministry said Friday it has conditionally approved the production and sales of two regenerative medical products using induced pluripotent stem cells. The approval was given to ...

Nina Bauer of FUJIFILM Cellular Dynamics shares insight on addressing challenges and supporting developers heading towards commercialization.

The Japanese government on Friday conditionally approved the commercialization of two regenerative medicine products prepared from induced pluripotent ...